Copyright© 2010 TheraTorr Medical, Inc. All Rights Reserved.
Timothy E. Moutafis, B.S. - Founder
Tim is a highly creative entrepreneur and engineer with more than 25 years of experience developing products in the
biomedical technology field. He founded HydroCision in 1994, which develops and markets surgical
instruments based on proprietary Fluidjet; technology. From 1991-94, he managed his own product
development consulting firm, serving many of the leading medical device companies in Massachusetts.
Mr. Moutafis was the Internal Entrepreneur at C.R. Bard, Inc., Senior Biomedical Engineer at Abiomed and a staff
engineer at Loeffler/MacConkey and Barry Wright Corporation. He has 35 US and International patents.
Don Freeman, Jr., Ph.D.
Dr. Freeman retired as the President/CEO of HydroCision, Inc. in 2002. He is currently on the board of directors of
Medical Record Bank, Electrolyzer Corporation, Respiratory Motion, and Pluromed.
Prior to HydroCision, he was Chairman/CEO of RadioMed Corporation, which was acquired by IBA. Previously, he
was President/CEO & Director at Intra-Sonix, a principal at Grayson Associates, a mid-market investment Bank,
CEO & Director at Xenotech Laboratories, Group Vice President at C.R. Bard, Inc., President of Davol (acquired by
C.R. Bard), and Corporate Director of New Business Development at Union Carbide after starting as a scientist with
the Linde Division of Union Carbide.
Dr. Freeman holds an ScB Degree from Brown and a PhD in chemistry from the University of Maryland, and did
post-doctoral research in physics at Duke. He completed the Advanced Management Program at Harvard Business
School. Don is a member at Boston Harbor Angels and is active in the MassMedic Ignite Program.
Dr. Ullrich Schwertschlag, MD, PhD, FACP - Medical Advisor
Dr. Schwertschlag is currently Chief Medical Officer of Attogen, Inc., and an Adjunct Associate Professor in
Pharmacology and Experimental Therapeutics at Tufts University, MA.
Dr. Schwertschlag has over twenty years of experience in senior clinical development roles in the
biopharmaceutical industry including large pharma and small biotech. He has extensive experience in translational
research, as well as preclinical and clinical development for drugs in major disease areas including oncology,
neurology, gastrointestinal diseases, immunology and inflammation. Additional competencies are in patient care,
preclinical laboratory investigation and FDA interactions/filings.
Dr. Schwertschlag completed his medical training (MD) at the University of Heidelberg and received his Ph.D. in
biophysics from the University of Freiburg, both Germany. He did his internship and residency at University
Heidelberg and Freiburg Hospitals in internal medicine and critical care. He accomplished postdoctoral training in
pharmacology at the University of Heidelberg and a clinical fellowship/housestaff training at the University of
Colorado Medical Center. He was an assistant professor and attending physician in internal medicine at Duke
University Medical Center, NC and the IUPUI hospitals and the VA medical center, IN.